ADYNXX SUB, INC.

Address: 44 TEHAMA ST SAN FRANCISCO, CA 94105-3110
County: SAN FRANCISCO
Country: UNITED STATES
UEI: LQKTZ3CEHZV5

Issue Date FY

Legal Entity Zip Code

Issue Date FY: 2021 ( Subtotal = -$2,126,906 )

2021

2020

ADYNXX SUB, INC.

44 TEHAMA ST

SAN FRANCISCO

94105-3110

SAN FRANCISCO

USA

UG3DA048375

The long-term reduction of pain and opioid usage following mastectomy and tissue expander/implant surgery with a single administration of brivoligide, a non-opioid, disease-modifying drug candidate

001

NIH

8/23/2021

-$1,524,390

2021

2020

ADYNXX SUB, INC.

44 TEHAMA ST

SAN FRANCISCO

94105-3110

SAN FRANCISCO

USA

UG3DA048375

The long-term reduction of pain and opioid usage following mastectomy and tissue expander/implant surgery with a single administration of brivoligide, a non-opioid, disease-modifying drug candidate

000

NIH

12/10/2020

2021

2019

ADYNXX SUB, INC.

44 TEHAMA ST

SAN FRANCISCO

94105-3110

SAN FRANCISCO

USA

R43NS113726

Pharmacokinetic and toxicology studies of AYX2, a transcription factor decoy, non-opioid, disease modifying drug candidate for the long-term treatment of chronic pain

000

NIH

8/10/2021

-$602,516

Issue Date FY: 2020 ( Subtotal = $2,858,544 )

2020

ADYNXX SUB, INC.

44 TEHAMA ST

SAN FRANCISCO

94105-3110

SAN FRANCISCO

USA

UG3DA048375

The long-term reduction of pain and opioid usage following mastectomy and tissue expander/implant surgery with a single administration of brivoligide, a non-opioid, disease-modifying drug candidate

002

NIH

9/8/2020

$2,858,544

2020

ADYNXX, INC.

100 PINE ST STE 500

SAN FRANCISCO

94111-5103

SAN FRANCISCO

USA

UG3DA048375

The long-term reduction of pain and opioid usage following mastectomy and tissue expander/implant surgery with a single administration of brivoligide, a non-opioid, disease-modifying drug candidate

000

NIH

12/12/2019

$2,572,690

2020

ADYNXX SUB, INC.

44 TEHAMA ST

SAN FRANCISCO

94105-3110

SAN FRANCISCO

USA

UG3DA048375

The long-term reduction of pain and opioid usage following mastectomy and tissue expander/implant surgery with a single administration of brivoligide, a non-opioid, disease-modifying drug candidate

002

NIH

9/8/2020

-$2,858,544

2020

ADYNXX, INC.

100 PINE ST STE 500

SAN FRANCISCO

94111-5103

SAN FRANCISCO

USA

UG3DA048375

The long-term reduction of pain and opioid usage following mastectomy and tissue expander/implant surgery with a single administration of brivoligide, a non-opioid, disease-modifying drug candidate

001

NIH

2/10/2020

$285,854

Issue Date FY: 2019 ( Subtotal = $3,461,060 )

2019

ADYNXX, INC.

100 PINE ST STE 500

SAN FRANCISCO

94111-5103

SAN FRANCISCO

USA

R43NS113726

Pharmacokinetic and toxicology studies of AYX2, a transcription factor decoy, non-opioid, disease modifying drug candidate for the long-term treatment of chronic pain

000

NIH

9/23/2019

$602,516

2019

ADYNXX, INC.

100 PINE ST STE 500

SAN FRANCISCO

94111-5103

SAN FRANCISCO

USA

UG3DA048375

The long-term reduction of pain and opioid usage following mastectomy and tissue expander/implant surgery with a single administration of brivoligide, a non-opioid, disease-modifying drug candidate

000

NIH

12/7/2018

$2,858,544

All Categories

About

Search

Reports

Data Submission

Recipient Information

ADYNXX SUB, INC.

Address: 44 TEHAMA ST SAN FRANCISCO, CA 94105-3110

County: SAN FRANCISCO

Country: UNITED STATES

UEI: LQKTZ3CEHZV5

Issue Date FY Summary

Issue Date FY by OPDIV

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer